Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Protalix BioTherapeutics (PLX) Reports Q1 Loss of $0.48/Shre

Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update

May 10, 2017 7:30 AM EDT

Positive Results from Phase II Trial in CF Program with Number of Potential Strategic Alternatives for Further Development

First Ever Once Monthly Dosing Trial in Fabry Patients to Commence Next Quarter

Continued Progress in the Commercialization of alfataliglicerase in Brazil

CARMIEL, Israel, May 10, 2017 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based... More